8,700 Studies Reviewed. 87.0% Found Biological Effects. The Evidence is Clear.
Shield Your Body
Whole Body / General

Transcriptomic profiling of human mesenchymal stem cells using a pulsed electromagnetic-wave motion bioreactor 143 system for enhanced osteogenic commitment and therapeutic potentials

Bioeffects Seen

Randhawa A, Ganguly K, Dutta SD, Patil TV, Lim K-T · 2025

Share:

Dynamic pEMF stimulation in a wave-motion bioreactor system can significantly enhance both the proliferation and osteogenic differentiation of hBMSCs while promoting cellular antioxidant properties.

Plain English Summary

Summary written for general audiences

This study examined how pulsed electromagnetic fields (pEMF) combined with wave-motion bioreactor systems affect human bone marrow-derived mesenchymal stem cells (hBMSCs). The researchers found that 30-minute pEMF exposures enhanced cell proliferation, increased osteogenic (bone-forming) gene expression, and induced reactive oxygen species (ROS)-scavenging properties in the cultured cells.

Why This Matters

This research demonstrates an application of electromagnetic field stimulation in regenerative medicine and tissue engineering. The study uses transcriptomic profiling to characterize molecular-level changes, providing mechanistic insight into how physical stimulation can modulate stem cell behavior.

Exposure Information

Specific exposure levels were not quantified in this study.

Watch: Video About This Study

Cite This Study
Randhawa A, Ganguly K, Dutta SD, Patil TV, Lim K-T (2025). Transcriptomic profiling of human mesenchymal stem cells using a pulsed electromagnetic-wave motion bioreactor 143 system for enhanced osteogenic commitment and therapeutic potentials.
Show BibTeX
@article{randhawa_a_ganguly_k_dutta_sd_patil_tv_lim_k_t_ce4187,
  author = {Randhawa A and Ganguly K and Dutta SD and Patil TV and Lim K-T},
  title = {Transcriptomic profiling of human mesenchymal stem cells using a pulsed electromagnetic-wave motion bioreactor 143 system for enhanced osteogenic commitment and therapeutic potentials},
  year = {2025},
  doi = {10.1016/s1473-3099(25)00093-3},
  
}
DOI: 10.1016/s1473-3099(25)00093-3PubMed: 39084096

Quick Questions About This Study

This appears to be a database classification error. The study examined oral COVID-19 medications, not electromagnetic field exposure, and should not be included in EMF health research collections.
The RECOVERY trial tested whether adding molnupiravir or nirmatrelvir-ritonavir antiviral drugs to usual care improved outcomes in hospitalized COVID-19 patients. It found no significant clinical benefits.
The molnupiravir comparison included 923 participants (445 treatment, 478 control), while the nirmatrelvir-ritonavir comparison included 137 participants (68 treatment, 69 control) across multiple hospitals.
Both antiviral treatments showed identical 17-19% mortality rates compared to usual care alone, with no statistically significant differences in 28-day survival outcomes between treatment and control groups.
Both antiviral comparisons were stopped due to low patient recruitment, which limited the study's ability to detect clinically meaningful treatment benefits, particularly for the smaller nirmatrelvir-ritonavir group.